Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 387

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Aspirin Use to Prevent Cardiovascular Disease: US Preventive Services Task Force Recommendation Statement

Open access
US Preventive Services Task Force, Davidson, Karina W., Barry, Michael J., Mangione, Carol M., Cabana, Michael, Chelmow, David, Coker, Tumaini Rucker, Davis, Esa M., Donahue, Katrina E., Jaén, Carlos Roberto, Krist, Alex H., Kubik, Martha, Li, Li, Ogedegbe, Gbenga, Pbert, Lori, Ruiz, John M., Stevermer, James, Tseng, Chien-Wen, Wong, John B. · 2022 · JAMA

Abstract

Importance: Cardiovascular disease (CVD) is the leading cause of mortality in the US, accounting for more than 1 in 4 deaths. Each year, an estimated 605 000 people in the US have a first myocardial infarction and an estimated 610 000 experience a first stroke. Objective: To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the effectiveness of aspirin to reduce the risk of CVD events (myocardial infarction and stroke), cardiovascular mortality, and all-cause mortality in persons without a history of CVD. The systematic review also investigated the effect of aspirin use on colorectal cancer (CRC) incidence and mortality in primary CVD prevention populations, as well as the harms (particularly bleeding) associated with aspirin use. The USPSTF also commissioned a microsimulation modeling study to assess the net balance of benefits and harms from aspirin use for primary prevention of CVD and CRC, stratified by age, sex, and CVD risk level. Population: Adults 40 years or older without signs or symptoms of CVD or known CVD (including history of myocardial infarction or stroke) who are not at increased risk for bleeding (eg, no history of gastrointestinal ulcers, recent bleeding, other medical conditions, or use of medications that increase bleeding risk). Evidence Assessment: The USPSTF concludes with moderate certainty that aspirin use for the primary prevention of CVD events in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk has a small net benefit. The USPSTF concludes with moderate certainty that initiating aspirin use for the primary prevention of CVD events in adults 60 years or older has no net benefit. Recommendation: The decision to initiate low-dose aspirin use for the primary prevention of CVD in adults aged 40 to 59 years who have a 10% or greater 10-year CVD risk should be an individual one. Evidence indicates that the net benefit of aspirin use in this group is small. Persons who are not at increased risk for bleeding and are willing to take low-dose aspirin daily are more likely to benefit. (C recommendation) The USPSTF recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults 60 years or older. (D recommendation).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jama.2022.4983

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 5

  1. Heron, 2019, Deaths: leading causes for 2017., Natl Vital Stat Rep, 68, 1
  2. de Groot, 2014, Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts., J Gastroenterol, 49, 245, 10.1007/s00535-013-0817-y · doi:10.1007/s00535-013-0817-y
  3. Nemerovski, 2012, Aspirin for primary prevention of cardiovascular disease events., Pharmacotherapy, 32, 1020, 10.1002/phar.2012.32.issue-11 · doi:10.1002/phar.2012.32.issue-11
  4. Guirguis-Blake, 2022, Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: An Evidence Update for the US Preventive Services Task Force. Evidence Synthesis No. 211, 10.1001/jama.2022.3337 · DOI · Paper page
  5. Dehmer, 2022, Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: An Updated Decision Analysis for the US Preventive Services Task Force, 10.1001/jama.2022.3385 · DOI

Cited by

See all 387

Metadata

Authors
US Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Chelmow, D., Coker, T. R., Davis, E. M., Donahue, K. E., Jaén, C. R., Krist, A. H., Kubik, M., Li, L., Ogedegbe, G., Pbert, L., Ruiz, J. M., Stevermer, J., Tseng, C.-W., & Wong, J. B.
Venue
JAMA
Published
2022-04-26
Volume
327
Issue
16
Pages
1577
ISSN
  • 0002-9955 (ISSN-L)
  • 0098-7484
OpenAlex
W4224925677
Cited by
387
References
30
FWCI
51.62
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.